Solid tumor
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Solid tumor patients aged over 18 years (including 18 years old, subject to the time of signing the informed consent form) who need to use cisplatin chemotherapy; 2. Fully understand the purpose, nature, method and possible adverse reactions of the research, and voluntarily sign a written informed consent; 3. Not pregnant or breastfeeding; 4. No change in chronic disease drug treatment within 2 weeks before the start of the study; 5. Baseline serum creatinine clearance >=60 mL/min/1.73m^2.
Exclusion criteria
Exclusion criteria: 1. Allergic to cisplatin or contraindications to chemotherapy; 2. Allergy to benzimidazoles or other contraindications to proton pump inhibitors; 3. The use of contrast agents or the use of nephrotoxic drugs (such as aminoglycosides, amphotericin B, etc.) within 1 week before the start of the study; 4. Patients diagnosed with renal cancer or abnormal baseline serum creatinine and baseline blood urea nitrogen; 5. ECOG PS >=2 points; 6. Patients using OCT2 substrates or inhibitors; 7. Abnormal liver function indicators (ALT or AST>=3xULN); 8. Those with a history of nephrectomy; 9. Participants with history of organ transplantation or renal dialysis or participants who need organ transplantation or kidney dialysis; 10. Patients with chronic heart failure who cannot receive more than 1L of fluid; 11. Participated in other drug clinical studies within 3 months before the start of the study; 12. Any other situation that the investigator believes may affect the patient's following the research protocol, or the patient's participation in the research may affect the research results or their own safety.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood urea nitrogen; | — |
Countries
China
Contacts
Ankang People's Hospital